• Skip to primary navigation
  • Skip to main content
  • Skip to footer
PanTher Therapeutics

PanTher Therapeutics

  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact
homePress ReleasePanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer

June 17, 2021 Press Release

PanTher announces today that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures (CHV), with participation by Angel Physicians Fund (APF) and other notable investors. The Series A round brings the total amount raised by the company to $7.4M. Proceeds from the funding will go toward the company’s first-in-human clinical trial. The company also announced today the additions of Darshana Zaveri, Managing Partner at CHV, Manish Bhandari, Managing Partner at APF, and Maria Palasis, President and CEO of Lyra Therapeutics, to its board of directors. “PanTher represents a truly new therapeutic modality that has the potential to change the way we deliver lifesaving drugs to tumors,” noted Zaveri.

Footer

Twitter LinkedIn

PanTher Therapeutics, Inc

191 Dexter Ave
Watertown, MA, 02472

PanTher Therapeutics © 2022 All Rights Reserved

Terms of Use Privacy Policy Cookie Policy Accessibility Statement

logo
  • About Us
    • Mission
    • Team
  • Our Technology
    • Platform
    • Products
  • News
  • Careers
  • Contact